Banque Pictet & Cie SA Has $9.13 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Banque Pictet & Cie SA lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,822 shares of the biopharmaceutical company’s stock after buying an additional 1,234 shares during the period. Banque Pictet & Cie SA’s holdings in Regeneron Pharmaceuticals were worth $9,125,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Board of the Pension Protection Fund acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, Berbice Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of Regeneron Pharmaceuticals stock opened at $777.25 on Thursday. The business’s 50 day simple moving average is $766.33 and its 200 day simple moving average is $711.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a market cap of $82.17 billion, a PE ratio of 18.70, a P/E/G ratio of 2.07 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.07 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. Guggenheim increased their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Barclays assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an “overweight” rating and a $923.00 price target on the stock. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $804.70.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 5,274 shares of company stock worth $4,142,738. Company insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.